# Aktis Oncology (AKTS) — News

AKTS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/akts/news

## Recent headlines

- [Trading released/resumed: (Attiu) Reason not available](https://www.ainvest.com/news/trading-released-resumed-attiu-reason-2610) — AInvest Wire, Oct 13, 2026
  Trading in the security known as "Attiu" has been temporarily halted, with the resumption date and reason for the halt not currently available to the public. Trading pauses are typically implemented to address market irregularities, ensure fair trading practices, or allow for dissemination of…
- [Oppenheimer initiates coverage with outperform rating; target price $70](https://www.ainvest.com/news/oppenheimer-initiates-coverage-outperform-rating-target-price-70-2610) — AInvest Wire, Oct 1, 2026
  Oppenheimer has initiated coverage on Aktis Oncology Inc (NASDAQ: AKTS) with an "Outperform" rating and a target price of $40 . The firm's decision is based on confidence in Aktis’ innovative miniprotein conjugate platform and its two clinical-stage candidates, AKY-1189 and AKY-2519, which are…
- [Aktis Oncology - Enrollment ongoing in phase 1B Nectinium-2 trial of Aky-1189; data expected Q1 2027](https://www.ainvest.com/news/aktis-oncology-enrollment-ongoing-phase-1b-nectinium-2-trial-aky-1189-data-expected-q1-2027-2610) — AInvest Wire, Oct 1, 2026
  Aktis Oncology (AKTS) continues enrollment in its phase 1B Nectinium-2 trial of Aky-1189, a clinical candidate in the field of oncology. The trial is part of the company’s ongoing research and development efforts. Data from the trial is anticipated in the first quarter of 2027, which may provide…
- [Aktis Oncology - Preliminary data from phase 1B Bactinium-1 trial expected in 2027](https://www.ainvest.com/news/aktis-oncology-preliminary-data-phase-1b-bactinium-1-trial-expected-2027-2610) — AInvest Wire, Oct 1, 2026
- [Aktis Oncology Inc: Oppenheimer initiates coverage with outperform rating; price target $40](https://www.ainvest.com/news/aktis-oncology-oppenheimer-initiates-coverage-outperform-rating-price-target-40-2609) — AInvest Wire, Sep 9, 2026
  Oppenheimer & Co. has initiated coverage of Aktis Oncology, Inc. (AKTS) with an "outperform" rating and a price target of $40 per share. The move comes as the firm begins to evaluate the biopharmaceutical company, which is focused on developing targeted therapies for oncology indications. The…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).